PTEN-mediated pathways and their association with treatment-resistant prostate cancer

BJU International

Volumn 104, Issue 4, 2009, Pages 556-561

  Uzoh, Christopher C ^a   Perks, Claire M ^b   Bahl, Amit ^c   Holly, Jeff M P ^b   Sugiono, Marto ^d   Persad, Raj A ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Akt; Apoptosis; Progression; Prostate cancer; PTEN9; Treatment failure

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROGEN RECEPTOR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS SIGNAL REGULATING KINASE 1; EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; SF 1126; TEMSIROLIMUS; UNCLASSIFIED DRUG; VQD 002; XL 147; ONCOPROTEIN; PTEN PROTEIN, HUMAN;

APOPTOSIS; CANCER CELL; CANCER INVASION; CANCER RECURRENCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE MUTATION; HORMONAL THERAPY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG RESISTANCE; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEIN V-AKT; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TREATMENT FAILURE;

EID: 69849102272     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08411.x     Document Type: Review

References (38)

1. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275 : 1943-1947
2. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 2005; 307 : 1098-1101
3. Li L, Ittmann MM, Ayala G et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005; 8 : 108-118 (Pubitemid 43118073)
4. Shen MM, Abate-Shen C. PTEN inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007; 67 : 6535-6538
5. Huang H, Cheville JC, Pan Y et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 Expression. J Biol Chem 2001; 276 : 38830-38836
6. Priulla M, Calastretti A, Bruno P et al. Preferential chemosensitization of PTENmutated prostate cells by silencing the Akt kinase. Prostate 2007; 67 : 782-789
7. Anai S, Goodison S, Shiverck K et al. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther 2006; 17 : 975-984
8. Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer tropism to the bone microenvironment. Carcinogenesis 2007; 28 : 1393-1400
9. Bedolla R, Prihoda TJ, Kreisberg JI et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13 : 3860-3867
10. Pourmand G, Ziaee A, Adedi AR et al. Role of PTEN Gene in progression of prostate cancer. Urol J 2007; 4: 95 100
11. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol-3,4,5- triphosphates. J Biol Chem 1998; 273: 13375-13378
12. Ermoian RP, Furniss CS, Lamborn KR et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 2002; 8: 1100-1106
13. Virolle T, Adamson ED, Baron V et al. The Egr-1 transcription factor directly activates PTEN during irradiation induced signaling. Nat Cell Biol 2001; 3: 1124-1128
14. Blanco-Aparicio C, Renner O, Leal JFM et al. PTEN, more than the Akt pathway. Carcinogenesis 2007; 28: 1379 86
15. Dahia PLM. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000; 7: 115-129
16. Kotelevets L, van Hengel J, Bruyneel E et al. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol 2001; 155: 1129-1135
17. Zhao H, Dupont J, Yakar S et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004; 23: 786-794
18. Zhou YJ, Xiong YX, Wu XT et al. Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastoenterol 2004; 1: 3225-3229
19. Gottlob K, Majewski N, Kennedy S et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15: 1406-1418
20. Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1- dependent pathways. Nat Med 2004; 10: 594-601
21. Ziello JE, Jovin IS, Huang Y. Hypoxiainducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 2007; 80: 51-60
22. Grunwald V, DeGraffenried L, Russel D et al. Inhibitors of mTOR reverse doxorubicin resistance confered by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-6145
23. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390
24. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogenactivated protein (MAP) kinase signalling pathways. J Cell Biol 1998; 143: 1375-1383
25. Wu Z, Gioeli D, Conaway M et al. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008; 68: 935-944
26. Misra UK, Deedwania R, Pizzo SV. Activation and cross-talk between Akt, NF-êB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surfaceassociated GRP78. J Biol Chem 2006; 281: 13694-13707
27. Kwabi-Addo B, Giri D, Schmidt K et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001; 98: 11563-11568
28. Trotman LC, Niki M, Dotan ZA et al. PTEN dose dictates cancer progression in the prostate. Plos Biol 2003; 1: 385-396
29. Forrest MS, Edwards SM, Hamondi RA et al. No evidence of germ-line PTEN mutation on familial prostate cancer. J Med Genet 2000; 37: 210-212
30. Yuan X, Whang YE. PTEN sensitizes prostate cancer cells to death receptormediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002; 21: 319-327
31. Liu Y, Wang J, Guo J et al. DUSP1 Is controlled by p53 during the cellular response to oxidative stress. Mol Cancer Res 2008; 6: 624-633
32. Nan B, Snabboon T, Unni E et al. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003; 31: 169-183
33. Lin H, Hu Y, Lee DK et al. Regulation of androgen receptor signaling by PTEN tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 2004; 18: 2409-2423
34. Wu Z, Conaway W, Gioeli D et al. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 2006; 66: 1114 23
35. Bandyopadhayay S, Pai SK, Hirota S et al. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res 2004; 64: 7655-7660 (Pubitemid 39446890)
36. Moorehead RA, Hojilla CV, De Belle I et al. Insulin like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem 2003; 278: 50422-50427
37. Stambolic V, MacPherson D, Sas D et al. Regulation of PTEN Transcription by p53. Mol Cell 2001; 8: 317-325
38. Perks CM, Vernon EG, Rosendahl AH et al. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007; 26: 5966-5972